中文名称 | 4-((S)-2-((S)-2-(6-(2,5-二氧代-2,5-二氢-1H-吡咯-1-基)己酰胺)-3-甲基丁酰胺)-5-脲基戊酰胺)苄基((S)-1-(((S)-1-(((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1S,2R)-1-羟基-1-苯丙烷-2-基)氨基)-1-甲氧基-2-甲基-3-氧代丙基)吡咯烷-1-基)-3-甲氧基-5-甲基-1-氧代庚-4-基)(甲基)氨基)-3-甲基-1-氧代丁烷-2-基)氨基)-3-甲基-1-氧代丁烷-2-基)(甲基)氨基甲酸酯 |
---|---|
英文名称 | VcMMAE; Maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl-monomethyl auristatin E; Mc-Val-Cit-PAB-MMAE |
CAS号 | 646502-53-6 |
分子式 | C68H105N11O15 |
分子量 | 1,316.63 |
储存条件 | Avoid light, nitrogen, -20 ℃ |
VcMMAE (mc-vc-PAB-MMAE), a MMAE derivative with valine-citrulline (Vc) linker,is an Drug-linker Conjugate for antibody-drug conjugate (ADC) with potent antitumor activity. MMAE is a synthetic antineoplastic agent and can be efficiently released from VcMMAE in vitro and exert cytotoxic activity.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft